Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating reaffirmed by equities research analysts at B. Riley in a research report issued on Monday. They presently have a $220.00 target price on the biopharmaceutical company’s stock. B. Riley’s price target points to a potential upside of 73.35% from the stock’s current price.

A number of other analysts have also recently issued reports on ALNY. Jefferies Group boosted their target price on Alnylam Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a report on Tuesday, September 26th. Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $62.00 to $163.00 in a report on Monday, October 2nd. BidaskClub cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $146.00 target price (up previously from $90.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 21st. Finally, Cowen reiterated an “outperform” rating and set a $117.00 target price (up previously from $93.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 20th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and sixteen have issued a buy rating to the company’s stock. Alnylam Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $121.85.

Alnylam Pharmaceuticals (ALNY) traded down $1.29 during midday trading on Monday, hitting $126.91. 389,630 shares of the stock were exchanged, compared to its average volume of 1,144,818. Alnylam Pharmaceuticals has a one year low of $35.98 and a one year high of $147.63. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $28.15 million. During the same quarter in the previous year, the firm posted ($1.21) EPS. The firm’s revenue for the quarter was up 24.8% compared to the same quarter last year. analysts expect that Alnylam Pharmaceuticals will post -5.21 earnings per share for the current fiscal year.

In other news, SVP Laurie Keating sold 30,000 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the completion of the transaction, the senior vice president now directly owns 41,500 shares in the company, valued at approximately $5,639,435. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Barry E. Greene sold 85,316 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $125.00, for a total value of $10,664,500.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 393,212 shares of company stock valued at $48,109,436. 4.30% of the stock is owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in the company. State of Wisconsin Investment Board boosted its stake in shares of Alnylam Pharmaceuticals by 0.7% during the 2nd quarter. State of Wisconsin Investment Board now owns 15,012 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 100 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares during the last quarter. Utah Retirement Systems boosted its stake in shares of Alnylam Pharmaceuticals by 1.5% during the 2nd quarter. Utah Retirement Systems now owns 13,800 shares of the biopharmaceutical company’s stock valued at $1,100,000 after buying an additional 200 shares during the last quarter. Prudential Financial Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 4.8% during the 2nd quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 200 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its stake in shares of Alnylam Pharmaceuticals by 0.8% during the 2nd quarter. Alliancebernstein L.P. now owns 47,873 shares of the biopharmaceutical company’s stock valued at $3,818,000 after buying an additional 398 shares during the last quarter. Institutional investors own 88.43% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Alnylam Pharmaceuticals’ (ALNY) Buy Rating Reiterated at B. Riley” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/12/12/alnylam-pharmaceuticals-alny-buy-rating-reiterated-at-b-riley.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.